Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kerstin Maria Kampa-Schittenhelm"'
Autor:
Mihada Bajrami Saipi, Alessia Ruiba, Marcus Matthias Schittenhelm, Gunnar Blumenstock, Balázs Győrffy, Serena Fazio, Marlon Hafner, Anna-Lena Ahrens, Lara Aldinger, Vanessa Aellig, François G. Kavelaars, César Nombela-Arrieta, Falko Fend, Peter J. M. Valk, Driessen Christoph, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
Cell Death and Disease, Vol 15, Iss 11, Pp 1-13 (2024)
Abstract Apoptosis-stimulating proteins of p53 (ASPPs) are a family of proteins that modulate key tumor suppressor pathways via direct interaction with p53. Deregulation of these proteins promotes cancer development and impairs sensitivity to systemi
Externí odkaz:
https://doaj.org/article/793637dff01642d6878a7b3b72ca88da
Autor:
Marcus Matthias Schittenhelm, Bianca Walter, Vasileia Tsintari, Birgit Federmann, Mihada Bajrami Saipi, Figen Akmut, Barbara Illing, Ulrike Mau-Holzmann, Falko Fend, Charles Darin Lopez, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
EBioMedicine, Vol 42, Iss , Pp 340-351 (2019)
Background: Apoptosis-stimulating Protein of TP53-2 (ASPP2) is a tumor suppressor enhancing TP53-mediated apoptosis via binding to the TP53 core domain. TP53 mutations found in cancers disrupt ASPP2 binding, arguing for an important role of ASPP2 in
Externí odkaz:
https://doaj.org/article/162a0dcf7af743ecb55394431c13be11
Autor:
Marcus Matthias Schittenhelm, Mihada Bajrami Saipi, Gunnar Blumenstock, Peter JM Valk, Balazs Györffy, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
Blood. 140:3433-3434
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1bea7e6ad7420a86f2adde1b788f3bc
https://doi.org/10.1182/blood-2022-170405
https://doi.org/10.1182/blood-2022-170405
Autor:
Rebecca Fröhlich, Kerstin Maria Kampa-Schittenhelm, Vasileia Tsintari, Marcus M. Schittenhelm
Publikováno v:
Blood. 138:3343-3343
In recent years, it has become increasingly apparent that BCL-2 inhibition in AML is a clinically highly effective approach - and the first BCL-2 inhibitor, venetoclax, has gained FDA and EMA approval. However, drug resistance frequently occurs and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f31dc9c461b4034de065cba80de91cf8
https://doi.org/10.1182/blood-2021-152312
https://doi.org/10.1182/blood-2021-152312
Autor:
Balazs Gyorffy, Max Kaiser, Kerstin Maria Kampa-Schittenhelm, Gunnar Blumenstock, Marcus M. Schittenhelm, Vasileia Tsintari
Publikováno v:
Blood. 138:1298-1298
ASPP1 (PPP1R13B) belongs to a family of p53-binding proteins and enhances apoptosis by stimulation of p53-transactivation of selected proapoptotic target genes. It is preferentially expressed in hematopoietic stem cells (HSC) and together with p53 pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9b7410f87a78b988a0b87d9f5a969bb
https://doi.org/10.1182/blood-2021-152531
https://doi.org/10.1182/blood-2021-152531
Autor:
Kerstin Maria, Kampa-Schittenhelm, Julia, Frey, Lara A, Haeusser, Barbara, Illing, Ashly A, Pavlovsky, Gunnar, Blumenstock, Marcus Matthias, Schittenhelm
Publikováno v:
Oncotarget
Activating D816 mutations of the class III receptor tyrosine kinase KIT are associated with the majority of patients with systemic mastocytosis (SM), but also core binding factor (CBF) AML, making KIT mutations attractive therapeutic targets for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c5283726e8645524484c955fc454d766
https://pubmed.ncbi.nlm.nih.gov/29137311
https://pubmed.ncbi.nlm.nih.gov/29137311